期刊
TRANSFUSION AND APHERESIS SCIENCE
卷 60, 期 3, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.transci.2021.103104
关键词
Rituximab; Convalescent plasma; COVID-19; Hypogammaglobulinemia
类别
The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.
Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据